4 completed, 3 recruiting, 2 active not recruiting, 2 terminated. 8 Phase 2, 7 Phase 1, 2 Not applicable.
Follow Progressive Disease: new trials by email Literature Review of Progressive Disease trials Research Report on Progressive Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Symptom Trajectory Approaches to Research Health surveys - Advanced Cancer, Metastatic Disease | Not yet recruiting | University of Wisconsin, Madison | 228 | 2026-12-01 | 2026-09-04 | |
| First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology - Astrocytoma, Glioblastoma | Phase 1 | Recruiting | Masonic Cancer Center, University of Minnesota | 9 | 2026-04-23 | 2026-05-01 |
| Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT Tacrolimus, Dexamethasone - Vitiligo, Child | Not applicable | Recruiting | Xijing Hospital | 90 | 2025-04-01 | 2025-06-19 |
| Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET Lutathera - Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor | Phase 2 | Recruiting | Institut du Cancer de Montpellier - Val d'Aurelle | 146 | 2021-10-18 | 2026-06-04 |
| CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome CPI-613, Hydroxychloroquine - Myelodysplastic Syndromes, Progressive Disease | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-05-01 | 2021-04-14 | |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 23 | 2020-03-04 | 2026-02-27 |
| Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer Binimetinib, Brigatinib - ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma | Phase 1 | Terminated | University of California, San Francisco | 3 | 2020-02-25 | 2022-10-17 |
| Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies Pembrolizumab, Autologous dendritic cells, Interleukin-2 - Mesothelioma, Malignant, PD-L1 Negative | Phase 1 | Active not recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 18 | 2019-12-12 | 2024-10-01 |
| sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Recombinant EphB4-HSA Fusion Protein - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Unknown | Northwestern University | 14 | 2019-09-20 | 2022-04-27 |
| Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Avelumab, Axitinib - Metastatic Adenoid Cystic Carcinoma, Progressive Disease | Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 2019-07-22 | 2024-10-18 |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Cetuximab, Encorafenib, Nivolumab - BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2019-06-14 | 2026-06-11 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Copanlisib, Niraparib - Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation | Phase 1 | Completed | M.D. Anderson Cancer Center | 31 | 2019-04-29 | 2026-07-23 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Best Practice, Laboratory Biomarker Analysis, Supportive Care - Acute Myeloid Leukemia, Brain Glioblastoma | Not applicable | Completed | Stanford University | 128 | 2017-08-08 | 2025-01-24 |
| Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive BKM120 - Head and Neck Neoplasms, Neoplasm Metastasis | Phase 2 | Completed | Centre Leon Berard | 58 | 2013-01-01 | 2019-06-24 |
Disease Progression (15) · Recurrence (3) · Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (2) · Myelodysplastic Syndromes (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Rectal Neoplasms (2) · Astrocytoma (1) · Bone Neoplasms (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1)
Disease Attributes (15) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Neoplasms (13) · Neoplasms by Histologic Type (7) · Neoplasms by Site (7) · Hemic and Lymphatic Diseases (4) · Neoplasms, Glandular and Epithelial (4) · Genital Diseases (3) · Hematologic Diseases (3) · Lung Diseases (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neoplastic Processes (3) · Neuroectodermal Tumors (3)
Cyclophosphamide (2) · fludarabine (2) · Axitinib (1) · Biopsy (1) · Blood Specimen Collection (1) · Cetuximab (1) · Dexamethasone (1) · Health Surveys (1) · Hydroxychloroquine (1) · Interleukin 1 Receptor Antagonist Protein (1) · Interleukin-2 (1) · NVP-BKM120 (1) · Nivolumab (1) · Palliative Care (1) · Practice Guidelines as Topic (1)
M.D. Anderson Cancer Center (4) · Centre Leon Berard (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Jonsson Comprehensive Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · Northwestern University (1) · Stanford University (1) · University of California, San Francisco (1) · University of Wisconsin, Madison (1) · Wake Forest University Health Sciences (1) · Xijing Hospital (1)
United States (11) · France (2) · China (1) · Italy (1)
Bayard Powell, MD (1) · Collin Blakely, MD, PhD (1) · Deshayes Emmanuel, PHD (1) · Jin S Im (1) · John M Timmerman, MD (1) · Kristine Kwekkeboom, PhD, RN, FAAN (1) · Maha H Hussain, M.D. (1) · Manali Patel (1) · Massimo Guidoboni, MD (1) · Renata Ferrarotto (1) · Roger Brown, PhD (1) · Shannon N Westin (1) · Van K Morris (1)
PMID 32379297, PMID 34749008, PMID 35771552, PMID 36210299, PMID 36898078, PMID 41528970
P30CA012197 (1), P30CA016672 (1), P30CA060553 (1), R01CA307143 (1)